2 not yet recruiting, 1 recruiting. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Not yet recruiting 2, Recruiting 1 |
Follow Thyroid Eye Disease, TED: new trials by email Literature Review of Thyroid Eye Disease, TED trials Research Report on Thyroid Eye Disease, TED
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Prophylactic Treatment of Graves Ophthalmopathy (GO) in Newly Diagnosed Graves' Disease (GD) With Atorvastatin (ATORGO) Atorvastatin - Graves Disease, Graves Disease (Basedow's Disease) | Phase 2 | Not yet recruiting | Region Skane | 554 | 2026-11-01 | 2026-10-20 |
| Teprotumumab N01 Versus Methylprednisolone After Urgent Orbital Decompression for Dysthyroid Optic Neuropathy Teprotumumab N01, Intravenous Methylprednisolone (IVMP) - Thyroid Eye Disease, TED, Graves Ophthalmopathy | Phase 2 | Not yet recruiting | Sun Yat-sen University | 60 | 2026-08-01 | 2026-05-19 |
| Tofacitinib for Glucocorticoid-Resistant Moderate-to-Severe Thyroid Eye Disease Tofacitinib - Thyroid Eye Disease, TED, Graves Ophthalmopathy | Phase 2 | Recruiting | The First Affiliated Hospital of Xiamen University | 8 | 2026-04-24 | 2026-04-29 |
Graves Ophthalmopathy (3) · Graves Disease (1) · Optic Nerve Diseases (1)
Autoimmune Diseases (3) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3) · Endocrine System Diseases (3) · Exophthalmos (3) · Eye Diseases (3) · Eye Diseases, Hereditary (3) · Genetic Diseases, Inborn (3) · Goiter (3) · Hyperthyroidism (3) · Immune System Diseases (3) · Orbital Diseases (3) · Thyroid Diseases (3) · Graves Disease (2) · Cranial Nerve Diseases (1) · Nervous System Diseases (1)
Atorvastatin (1) · Methylprednisolone (1) · Methylprednisolone Hemisuccinate (1) · teprotumumab (1) · tofacitinib (1)
Region Skane (1) · Sun Yat-sen University (1) · The First Affiliated Hospital of Xiamen University (1)
China (2) · Sweden (1)
Fangsen Xiao, MD (1) · Tereza Planck (1)
2023 (1)